Treatment with the MAO-A inhibitor clorgyline elevates monoamine neurotransmitter levels and improves affective phenotypes in a mouse model of Huntington disease

by Garcia-Miralles, Marta, Ooi, Jolene, Bardile, Costanza Ferrari, Tan, Liang Juin, George, Maya, Drum, Chester L, Lin, Rachel Yanping, Hayden, Michael R, Pouladi, Mahmoud A
Published 2022

Manipulation of microbiota reveals altered callosal myelination and white matter plasticity in a model of Huntington disease

by Radulescu, Carola I., Garcia-Miralles, Marta, Sidik, Harwin, Bardile, Costanza Ferrari, Nur Amirah Mohammad Yusof, Lee, Hae Ung, Ho, Eliza Xin Pei, Chu, Collins Wenhan, Layton, Emma, Low, Donovan, De Sessions, Paola Florez, Pettersson, Sven, Ginhoux, Florent, Pouladi, Mahmoud A.
Published 2021

Intrinsic mutant HTT-mediated defects in oligodendroglia cause myelination deficits and behavioral abnormalities in Huntington disease

by Bardile, Costanza Ferrari, Garcia-Miralles, Marta, Caron, Nicholas S., Rayan, Nirmala Arul, Langley, Sarah Raye, Harmston, Nathan, Rondelli, Ana Maria, Teo, Roy Tang Yi, Waltl, Sabine, Anderson, Lisa M., Bae, Han-Gyu, Jung, Sangyong, Williams, Anna, Prabhakar, Shyam, Petretto, Enrico, Hayden, Michael R., Pouladi, Mahmoud A.
Published 2020